MARKET

COLL

COLL

Collegium Pharmaceutical Inc
NASDAQ
24.21
-0.95
-3.78%
After Hours: 24.29 +0.08 +0.33% 19:30 11/06 EST
OPEN
24.06
PREV CLOSE
25.16
HIGH
24.80
LOW
23.71
VOLUME
775.58K
TURNOVER
--
52 WEEK HIGH
50.79
52 WEEK LOW
21.43
MARKET CAP
752.34M
P/E (TTM)
19.72
1D
5D
1M
3M
1Y
5Y
1D
Collegium Pharmaceutical Earnings Call Highlights ADHD Growth
TipRanks · 1d ago
Collegium Pharmaceutical (COLL) Gets a Buy from Truist Financial
TipRanks · 2d ago
Collegium Pharmaceutical Is Maintained at Neutral by Piper Sandler
Dow Jones · 2d ago
Collegium Pharmaceutical Price Target Cut to $28.00/Share From $43.00 by Piper Sandler
Dow Jones · 2d ago
Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28
Benzinga · 2d ago
Piper Sandler Reaffirms Their Hold Rating on Collegium Pharmaceutical (COLL)
TipRanks · 2d ago
Collegium’s Belbuca Resilience and ADHD Growth Support Buy Rating; $60 Price Target Unchanged
TipRanks · 2d ago
Collegium Pharmaceutical price target lowered to $28 from $43 at Piper Sandler
TipRanks · 2d ago
More
About COLL
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.

Webull offers Collegium Pharmaceutical Inc stock information, including NASDAQ: COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.